KS 01017
Alternative Names: KS 01 017Latest Information Update: 23 Jan 2013
At a glance
- Originator Abbott Laboratories
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lipid metabolism disorders; Metabolic syndrome